Replies to post #85821 on $heff's $tation of $tocks & $olid DD

[value1008]

MEIP - MEI Pharma’s Buy Rating Reiterated at Cantor Fitzgerald (MEIP)

http://www.americanbankingnews.com/2015/02/08/mei-pharmas-buy-rating-reiterated-at-cantor-fitzgerald-meip/

February 8th, 2015 • 0 comments • Filed Under • by ABMN Staff

MEI Pharma logoMEI Pharma (NASDAQ:MEIP)‘s stock had its “buy” rating restated by analysts at Cantor Fitzgerald in a researchreport issued to clients and investors on Sunday. They currently have a $14.00 price objective on the stock. Cantor Fitzgerald’s price target points to a potential upside of 250.00% from the company’s current price.

MEI Pharma (NASDAQ:MEIP) opened at 4.00 on Friday. MEI Pharma has a 1-year low of $3.57 and a 1-year high of $13.98. The stock’s 50-day moving average is $3.99 and its 200-day moving average is $6.22. The company’s market cap is $86.4 million.

A number of other firms have also recently commented on MEIP. Analysts at Wells Fargo & Co. initiated coverage on shares of MEI Pharma in a research note on Friday. They set an “outperform” rating and a $10.50 price target on the stock. Separately, analysts at Roth Capital lowered their price target on shares of MEI Pharma from $22.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th.

MEI Pharma, Inc, formerly Marshall Edwards, Inc, is a development-stage oncology company. The Company is engaged in the development of drugs for the treatment of cancer. The Company focuses on the clinical development of therapeutics targeting cancer metabolism. The Company is a wholly owned subsidiary of Novogen Limited (NASDAQ:MEIP).
______________________________________